Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 67
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT06711354 B-cell Depletion in Offspring to Women With MS Under Immunomodulatory T… |
Anti-CD20 Monoclonal Antibody | SEP | À vérifier | UNKNOWN | En attente / non publié | Region Stockholm | Non communiqué | 2025-06 → 2025-12 | Ouvrir |
| NCT04971005 COAST — Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoiet… |
Autologous Hematopoietic Stem Cel… | SEP | Phase 2 | TERMINATED | En attente / non publié | Universitätsklinikum Hamburg-Eppe… | Germany · Universitätsklinikum Hamburg-Eppendorf, Ham… | 2021-08-27 → 2022-02-04 | Ouvrir |
| NCT02807285 Expanded Access Program for Ocrelizumab in Participants With Primary Pr… |
Ocrelizumab | SEP | À vérifier | NO_LONGER_AVAILABLE | En attente / non publié | Hoffmann-La Roche | United States · Abington Neurological Associates, Wil… | Non communiqué | Ouvrir |
| NCT05123703 Operetta 2 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in … |
Ocrelizumab | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Argentina, Australia, Austria, Belgium… | 2022-05-19 → 2029-09-17 | Ouvrir |
| NCT04458688 Investigating the Effect of Ocrelizumab in African Americans and Caucas… |
Investigating the Effect of Ocrel… | SEP | À vérifier | RECRUITING | En attente / non publié | Wayne State University | United States · Wayne State University, Detroit, Unit… | 2021-11-20 → 2030-12 | Ouvrir |
| NCT05999604 WINDOCRE — Impact of Annual Versus Biannual Infusions of Ocrelizumab in… |
Ocrelizumab Injection [Ocrevus] | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Fondation Ophtalmologique Adolphe… | France · CH Gonesse, Gonesse, France | CHI Poissy-Sai… | 2023-11-09 → 2028-05 | Ouvrir |
| NCT04767698 Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multip… |
Belimumab | SEP | Phase 2 | TERMINATED | En attente / non publié | Johns Hopkins University | United States · Johns Hopkins University, Baltimore, … | 2021-10-01 → 2022-05-10 | Ouvrir |
| NCT06159712 CoSHEDRMS — Comparative Study of High-Efficacy Disease Modifying Treatm… |
CoSHEDRMS — Comparative Study of … | SEP | Non applicable | UNKNOWN | En attente / non publié | University of Aarhus | Denmark · Aarhus University, Aarhus, Denmark | 2023-11-27 → 2025-11 | Ouvrir |
| NCT04175834 PRECEPT — Comparing Risk and Severity of IRRs in Patients Premedicated … |
cetrizine | SEP | Phase 3 | COMPLETED | En attente / non publié | Providence Health & Services | United States · Providence Neurological Specialties W… | 2020-02-05 → 2022-05-13 | Ouvrir |
| NCT03138525 Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis |
Immune Profiling During Ocrelizum… | SEP | À vérifier | COMPLETED | En attente / non publié | Brigham and Women's Hospital | United States · Brigham and Women's Hospital, Boston,… | 2017-06-20 → 2019-12-20 | Ouvrir |
| NCT01247324 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in… |
Interferon beta-1a | SEP | Phase 3 | COMPLETED | En attente / non publié | German University in Cairo | United States, Argentina, Australia, Austria, Belgium… | 2011-08-31 → 2022-12-31 | Ouvrir |
| NCT06846281 Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in… |
Remibrutinib oral treatment | SEP | Phase 3 | RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States, Argentina, Australia, Belgium, Brazil,… | 2025-06-23 → 2031-06-25 | Ouvrir |
| NCT04544436 MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics… |
Ocrelizumab | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Argentina, Australia, Belgium, Brazil,… | 2020-11-26 → 2028-08-31 | Ouvrir |
| NCT05834855 Noisy Rebels — Non-inferiority Study of Rituximab Compared to Ocrelizum… |
Rituximab | SEP | Phase 3 | RECRUITING | En attente / non publié | M.D. Anderson Cancer Center | Netherlands · Amsterdam UMC, location VUmc, Amsterdam… | 2023-04 → 2027-05 | Ouvrir |
| NCT02545868 A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In P… |
23-PPV | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States, Canada · Abington Neurological Associa… | 2015-10-27 → 2021-09-21 | Ouvrir |
| NCT06586177 REBELLION-MS — Understanding the 'Durable Effect' Concept of B-cell Mod… |
Anti-CD20 antibody | SEP | À vérifier | RECRUITING | En attente / non publié | Heinrich-Heine University, Duesse… | Germany · Heinrich-Heine University, Duesseldorf, Düs… | 2021-10-27 → 2028-12-31 | Ouvrir |
| NCT05266469 Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in … |
Exploring the Profiles of RMS Pat… | SEP | À vérifier | COMPLETED | En attente / non publié | Novartis Pharmaceuticals | United Arab Emirates · Novartis Investigative Site, A… | 2022-07-26 → 2024-11-11 | Ouvrir |
| NCT07074886 PORTAMENTO — A Study to Assess Bioequivalence of Two Subcutaneous (SC) … |
Ocrelizumab Test Formulation | SEP | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Argentina, Brazil, France, Germany, It… | 2025-11-13 → 2030-03-31 | Ouvrir |
| NCT04035005 O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in … |
Ocrelizumab | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Australia, Belgium, Bulgaria, Canada, … | 2019-08-12 → 2028-01-19 | Ouvrir |
| NCT01765361 Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairm… |
Assessment of Ocrelizumab (OCR) T… | SEP | À vérifier | COMPLETED | En attente / non publié | University Hospital, Basel, Switz… | Switzerland · Dep. Neurology, Hospital of the Univers… | 2012-09 → 2017-01 | Ouvrir |
| NCT05269004 OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy … |
Ocrelizumab | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Argentina, Australia, Austria, Belarus… | 2022-05-03 → 2027-12-31 | Ouvrir |
| NCT07389590 Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis |
Ublituximab | SEP | Phase 4 | RECRUITING | En attente / non publié | TG Therapeutics, Inc. | United States · Johns Hopkins University, Baltimore, … | 2026-02-10 → 2029-03 | Ouvrir |
| NCT05232825 Ocarina II — A Phase III, Non-Inferiority, Randomized, Open-Label, Para… |
Ocrelizumab IV | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States, Brazil, Czechia, Italy, New Zealand, P… | 2022-05-03 → 2025-06-06 | Ouvrir |
| NCT06780150 SurfSubQ — A Study to Investigate Effects of Ocrelizumab Treatment on N… |
Ocrelizumab | SEP | À vérifier | RECRUITING | En attente / non publié | Hoffmann-La Roche | Germany, Switzerland · Allgemeines Krankenhaus Celle … | 2024-09-26 → 2028-03-31 | Ouvrir |
| NCT07667322 OCARINA 3 — A Study to Investigate the Safety, Tolerability, Pharmacoki… |
Ocrelizumab Co-formulated With rH… | SEP | Phase 1 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Brazil, Mexico, United Kingdom · Centr… | 2024-12-17 → 2028-08-01 | Ouvrir |